Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, Motta M, Quaglia FM, Trentin L, Ferrario A, Laurenti L, Reda G, Ferrari A, Pietrasanta D, Sportoletti P, Re F, De Paoli L, Foglietta M, Giordano A, Marchetti M, Farina L, Del Poeta G, Varettoni M, Chiurazzi F, Marasca R, Malerba L, Ibatici A, Tisi MC, Stefoni V, Leone M, Baratè C, Olivieri J, Murru R, Gentile M, Sanna A, Gozzetti A, Gattei V, Gottardi D, Derenzini E, Levato L, Orsucci L, Penna G, Chiarenza A, Foà R. Cuneo A, et al. Among authors: gottardi d. Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13. Hematol Oncol. 2021. PMID: 34258787 Free PMC article. No abstract available.
CD38 in chronic lymphocytic leukemia: from bench to bedside?
Deaglio S, Vaisitti T, Serra S, Audrito V, Bologna C, D'Arena G, Laurenti L, Gottardi D, Malavasi F. Deaglio S, et al. Among authors: d arena g, gottardi d. Mini Rev Med Chem. 2011 Jun;11(6):503-7. doi: 10.2174/138955711795843338. Mini Rev Med Chem. 2011. PMID: 21561406
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R. Saltarella I, et al. Among authors: gottardi d. J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4. J Hematol Oncol. 2019. PMID: 30626425 Free PMC article. Clinical Trial.
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S, Mazzocchi A, Pavoni C, Taverna F, Rossi A, Patti C, Romano A, Trentin L, Sorasio R, Guidetti A, Gottardi D, Tarella C, Cimminiello M, Zanotti R, Farina L, Ferreri AJM, Galbiati M, Corradini P, Gianni AM, Gallamini A, Rambaldi A. Viviani S, et al. Among authors: gottardi d. Hematol Oncol. 2020 Oct;38(4):501-508. doi: 10.1002/hon.2775. Epub 2020 Jul 30. Hematol Oncol. 2020. PMID: 32602970
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.
Mauro FR, Paoloni F, Molica S, Reda G, Trentin L, Sportoletti P, Marchetti M, Pietrasanta D, Marasca R, Gaidano G, Coscia M, Stelitano C, Mannina D, Di Renzo N, Ilariucci F, Liberati AM, Orsucci L, Re F, Tani M, Musuraca G, Gottardi D, Zinzani PL, Gozzetti A, Molinari A, Gentile M, Chiarenza A, Laurenti L, Varettoni M, Ibatici A, Murru R, Ruocco V, Del Giudice I, De Propris MS, Della Starza I, Raponi S, Nanni M, Fazi P, Neri A, Guarini A, Rigolin GM, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: gottardi d. Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207. Cancers (Basel). 2021. PMID: 35008372 Free PMC article.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: gottardi d. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
BCL-2 in B-chronic lymphocytic leukemia.
Caligaris-Cappio F, Ghia P, Gottardi D, Parvis G, Gregoretti MG, Nilsson K, Schena M. Caligaris-Cappio F, et al. Among authors: gottardi d. Curr Top Microbiol Immunol. 1992;182:279-86. doi: 10.1007/978-3-642-77633-5_34. Curr Top Microbiol Immunol. 1992. PMID: 1283367 No abstract available.
65 results